Nature Reviews Molecular Cell Biology Impact Factor

The impact factor tells you that articles in this journal are cited at one of the highest rates in all of science. But the number requires careful interpretation. Nature Reviews Molecular Cell Biology publishes approximately 49 citable items per year, all of them comprehensive reviews. Each review covers a major topic in molecular or cell biology and becomes the canonical reference for that area.

The five-year JIF of 128.7 running far above the two-year (90.2) shows the compounding effect: these reviews keep accumulating citations for years as the field continues to reference them. A single review in this journal can receive thousands of citations over its lifetime.

For context, the 73,135 total cites figure means that papers currently being cited in the JCR window from this journal are generating an extraordinary citation volume from a very small number of articles. That concentration is what produces the high JIF.

This table tells you two things. First, the journal's IF is genuinely volatile because it publishes only about 49 articles per year. A single blockbuster review can move the entire metric. The jump from ~35.6 in 2017 to ~94.4 in 2020 wasn't a gradual climb. It was driven by a few extraordinarily cited reviews in the pandemic era. Second, even the "low" years (35-38 in 2012-2015) would make NRMCB the highest-IF journal in most fields. The 2024 value of 90.2, rebounding from 81.3 in 2023, shows the journal hasn't permanently settled back from its 2021-2022 peak. The five-year JIF of 128.7 confirms extraordinary long-tail citation performance.

NRMCB is part of the Nature Reviews portfolio, a family of invitation-only review journals that collectively hold some of the highest impact factors in science. Here's how they compare.

Every Nature Reviews title ranks first in its JCR category. That's not a coincidence. It's the structural result of combining a review-only format with Nature's editorial selectivity and brand reach. Nature Reviews Drug Discovery leads the pack at 101.8, slightly above NRMCB's 90.2, largely because drug discovery reviews sit at the intersection of basic science, clinical medicine, and industry, three communities that all cite the same canonical reviews.

For researchers in molecular and cell biology, NRMCB's 90.2 is the benchmark for review-article prestige. But it's worth noting that all five journals operate on the same invitation-driven model. Being invited to write for any of them signals the same level of field authority.

In our pre-submission review work with researchers navigating the Nature Reviews Molecular Cell Biology pathway, three patterns consistently prevent researchers from securing an invitation or successfully delivering a commissioned review at this journal.

Proposals that summarize a field rather than advance a framework. The most common mistake in unsolicited proposals is pitching "a comprehensive review of [topic]" when what editors want is a new conceptual synthesis. NRMCB already has comprehensive coverage of most major topics. What earns an invitation or a positive response to a proposal is a genuinely new way of organizing or understanding a subfield, a new framework that connects disparate findings, a synthesis of two previously separated areas, or a paradigm-challenging reframing of a well-studied problem. "We will review autophagy in cancer" is a summary. "How autophagy switches between tumor-suppressive and tumor-promoting roles at different disease stages, and the mechanistic logic underlying that switch" is a framework.

Sending proposals too early in career trajectory. NRMCB editors track who is producing landmark primary research. Researchers who propose reviews before they have established themselves as leaders in their area, defined by multiple influential primary research papers and recognition at major conferences, rarely break through. The journal's reputation rests on reviews written by people who have genuinely advanced the field. A researcher with a strong single paper in an area does not meet that bar, and early proposals can work against you by signaling an impatience that experienced editors notice.

Choosing the wrong synthesis window. The strongest NRMCB proposals land when a field is at an inflection point, enough new findings have accumulated that the existing conceptual framework is straining, but the new synthesis has not yet been written. Proposals that arrive too early (before the field has enough data to support a new framework) or too late (after another group has published a similar synthesis) miss the window. Tracking the review literature in your area and identifying that inflection point (when the field needs a new organizing principle) is the strategic timing question that separates proposals that succeed from those that do not.

A NRMCB proposal scope and career-trajectory check of your primary research papers can assess whether the body of work supports the field-leader framing that NRMCB proposals require, and whether the mechanistic synthesis is genuinely novel or anticipates coverage another group is likely to publish first.

Several factors combine to produce one of the highest JIFs in science:

• Comprehensive reviews serve as citation entry points for entire subfields
• Molecular and cell biology is one of the largest and most heavily cited research areas
• The journal publishes very few articles per year (around 49), concentrating citation density
• Each review is written by leading experts and covers a topic comprehensively
• The Nature Reviews brand ensures maximum discoverability and readership
• Reviews accumulate citations over long periods as researchers keep referencing them in new papers

The 128.7 five-year JIF illustrates this compounding effect. Unlike primary research papers, which often peak in citations within the first two to three years, these reviews continue to climb.

Nature Reviews Molecular Cell Biology operates primarily on invitation. The editorial team identifies topics and invites experts to write comprehensive reviews. There are two paths:

1. Invitation from the editorial team: Editors track the field and invite recognized experts when a topic is ripe for a comprehensive review
2. Author-initiated proposal: Researchers can approach the editors with a proposal for a review topic, though acceptance of proposals is highly selective

For researchers who are building their review-writing profile, starting with shorter review formats in journals like Trends in Cell Biology, Current Opinion in Cell Biology, or Annual Review of Cell and Developmental Biology can build the track record that eventually leads to Nature Reviews invitations.

If you are planning a primary research submission in molecular or cell biology, Nature Reviews Molecular Cell Biology is not in your comparison set. The relevant targets are:

• Cell (IF 42.5): field-defining primary research across biology
• Nature Cell Biology (IF 19.1): strong primary cell biology with Nature branding
• Molecular Cell (IF 16.6): deep mechanistic molecular biology (Cell Press)
• Trends in Cell Biology (IF 18.1): shorter reviews and perspectives (also Cell Press)

For primary cell biology or molecular biology research, a NRMCB vs specialty journal fit check can help identify the right journal target based on the manuscript's strengths, scope, and the appropriate editorial bar.

Understanding why review journals have such high impact factors matters for evaluating any journal metric. A comprehensive review in molecular cell biology serves multiple citation functions:

• Researchers cite it in introductions to frame their own work
• Grant applicants reference it to establish the state of the field
• Students and new investigators use it as a learning entry point
• The review becomes the default citation for established concepts

These citation patterns are structural and persistent. They do not reflect the "importance" of a single review relative to a single primary research paper. They reflect a different publication type with different citation dynamics.

• Whether you will be invited to write for the journal
• How primary research journals compare to each other (the JIF is not on the same scale)
• Whether your review proposal will be accepted
• How hiring or promotion committees weight review authorship versus primary research
• The acceptance rate for unsolicited review proposals

The headline IF is 90.2, but the full JCR profile reveals something extraordinary. NRMCB doesn't just rank first in its category, it dominates by a margin that no other journal in molecular biology comes close to matching.

The 0 primary articles figure is the detail most people miss. JCR classifies NRMCB as publishing zero primary research. Every citable item is a commissioned review. That means the 90.2 IF comes entirely from review-article citation dynamics, no primary research papers diluting or inflating the average. The 5-year JIF of 128.7 running 43% above the 2-year IF shows these reviews don't just get cited once and forgotten. They become the canonical reference for their subfield, accumulating citations for years. At 73,135 total cites from roughly 49 articles per year, each review averages an astonishing citation footprint.

Most researchers can't just submit to NRMCB. Understanding how the journal operates is worth knowing, even if you're years away from being invited.

If you want to write for NRMCB, here's the realistic path. First, build a strong primary research record in your subfield, editors track who's producing field-shaping work. Second, write shorter reviews for journals like Trends in Cell Biology, Current Opinion in Cell Biology, or Annual Review of Cell and Developmental Biology. That builds your review-writing reputation. Third, if you have a genuinely novel synthesis angle on a hot topic, you can email the editors with a one-page proposal. Be specific about what's new in your framing, "a review of autophagy" won't work, but "how selective autophagy rewires metabolic signaling in stem cell fate decisions" might. The editors won't respond to most proposals, but a well-timed pitch on an under-reviewed topic occasionally breaks through.

Pursue if:

• you have an established primary research record with multiple high-impact papers defining your subfield
• you have identified a genuine synthesis gap, an area where a comprehensive review would change how the field thinks, not just summarize what's known
• you have already demonstrated review-writing capability through shorter formats (Trends journals, Current Opinion series, Annual Reviews)
• you are prepared to commit 6-12 months to writing a definitive, comprehensive synthesis

Think twice if:

• your primary research record is still early-stage (review authorship here is a career destination, not a career accelerator for newcomers)
• the proposed topic is already well-covered by recent NRMCB reviews (editors track what has been published and will not commission redundant coverage)
• the synthesis is a literature summary rather than a new framework or conceptual advance
• you are looking for a citable publication on a timeline, NRMCB reviews take 6-12 months and require sustained effort